Crossmark Global Holdings Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 46.0% in the 4th quarter, Holdings Channel reports. The fund owned 1,247 shares of the biopharmaceutical company’s stock after selling 1,061 shares during the period. Crossmark Global Holdings Inc.’s holdings in Regeneron Pharmaceuticals were worth $963,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $31,000. Torren Management LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $38,000. FNY Investment Advisers LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $38,000. Finally, Oakworth Capital Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 124.0% during the 4th quarter. Oakworth Capital Inc. now owns 56 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 31 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Regeneron Pharmaceuticals
In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.97% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on REGN
Regeneron Pharmaceuticals Stock Performance
Shares of REGN opened at $719.88 on Thursday. The firm has a market cap of $76.11 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 1.60 and a beta of 0.30. The company’s fifty day moving average is $747.55 and its 200-day moving average is $744.35. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 EPS. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
